PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

EC green-lights MSD’s Keytruda combo for lung cancer

Image


The European Commission has approved MSD’s Keytruda for use in combination with Eli Lilly’s Alimta and platinum-based chemotherapy for the first-line treatment of some advanced lung cancers.
Specifically, the decision allows use of the combination in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who have no EGFR or ALK positive mutations.
Keytruda (pembrolizumab) is the first immunotherapy to be approved by the EC for treatment of NSCLC in combination with chemotherapy, on the back of data from the KEYNOTE-189 trial, which showed that the combination cut the risk of death by more than 50% compared to Alimta (pemetrexed) and platinum-based chemotherapy alone.
A reduction in the risk of disease progression or death of 48% was also observed with pembrolizumab in combination with pemetrexed and platinum-based chemotherapy.
“This decision is likely to bring a step change in the way we treat lung cancer,” said Gary Middleton, Professor of Medical Oncology at the University of Birmingham. “It opens up treatment with pembrolizumab to anyone with non-squamous, non-small cell lung cancer, the most common type of lung cancer, that has spread to other parts of the body.”
“By combining immunotherapies with chemotherapy we are seeing remarkable benefits for patients, without adding a similar level of side-effects seen with chemotherapy on its own,” added Vanessa Beattie, chair of the National Lung Cancer Forum for Nurses and clinical nurse specialist at Aintree University Hospital, Liverpool.
The UK currently has the second worse survival rate for lung cancer in Europe with only 8% of patients surviving more than five years, highlighting the need for new treatment options and approaches.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026